EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment

Xinmei Chen, Zhixiang Wang iD

Cancers · 30.07.2026 · 18 (15) · 2451

DOI: 10.3390/cancers18152451 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.07.2026. Verfasst von Xinmei Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 291 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The epidermal growth factor receptor (EGFR) was the first receptor tyrosine kinase identified soon after v-Src was recognized as a tyrosine kinase. EGFR signaling begins when EGF binds to EGFR at the cell surface, inducing receptor dimerization, activation, and autophosphorylation. The resulting phosphotyrosine sites recruit downstream effectors that activate signaling cascades such as the RAS-RAF-MEK-ERK and PI3K-Akt pathways, thereby regulating cell growth, proliferation, and survival. EGF binding also promotes EGFR endocytosis, which can direct the receptor to lysosomal degradation. Aberrant EGFR activity is associated with many cancers, and the receptor has been therapeutically targeted using small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Furthermore, EGFR endocytosis has been exploited for the targeted delivery of anticancer agents into EGFR-expressing cancer cells through antibody–drug conjugates (ADCs) and antibody–nanoparticle conjugates (ANCs). Although ADCs and ANCs both utilize mAbs as homing mechanisms to recognize cancer-associated antigens, they further harness EGFR endocytosis to deliver therapeutic payloads directly into target cells. In this review, we briefly discuss EGFR structure, activation, signaling, and endocytosis, as well as the mechanisms underlying EGFR function in cancer development. We then focus on current advances and future perspectives in using EGFR endocytosis pathways to improve targeted cancer drug delivery and therapy, particularly in the context of ANCs.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugated (ADCs)antibody–nanoparticle conjugates (ANCs)cancerscell signalingdrug deliveryendocytosisepidermal growth factor (EGF) receptor (EGFR)targeted therapeutics

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada.

ORCID-Profile: Zhixiang Wang

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Chen, X., & Wang, Z. (2026). Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment. Cancers, 18(15), 2451. https://doi.org/10.3390/cancers18152451

Vancouver

Chen X, Wang Z. Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment. Cancers. 2026;18(15):2451. doi:10.3390/cancers18152451

BibTeX
@article{Chen2026,
  author = {Chen, Xinmei and Wang, Zhixiang},
  title = {Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2451},
  doi = {10.3390/cancers18152451}
}
Kostenlos starten →